You can buy or sell KRYS and other stocks, options, ETFs, and crypto commission-free!
Krystal Biotech, Inc. Common Stock, also called Krystal Biotech, is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. Read More It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
52 Week High
52 Week Low
Yahoo FinanceMar 7
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
Krystal Biotech, Inc. KRYS was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $22.00 to $23.30 in the past one-month time frame. The move came after the company announced the opening of a cGMP facility for the clinical and commercial production of its lead product KB10...
Seeking AlphaMar 6
Krystal Biotech christens new manufacturing facility for KB103
Krystal Biotech (KRYS +0.2% ) has officially opened its new 4,500 sq. ft. cGMP manufacturing facility for lead candidate KB103, an off-the-shelf topical gene therapy for an inherited skin disorder called dystrophic epidermolysis bullosa. Topline data from a Phase 2 study, GEM-1, should be available mid-year....
Stock Price, News, & Analysis for Krystal Biotech
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LL...
-$0.23 per share
-$0.28 per share